Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guaifenesin warning letter

This article was originally published in The Tan Sheet

Executive Summary

Carolina Pharmaceuticals' guaifenesin- and potassium guaiacolsulfonate-containing products are unapproved new drugs, FDA states in a March 12 warning letter citing Humibid L.A. and Humibid DM (which also contains dextromethorphan). The agency "is unaware of substantial scientific evidence" showing such a combination "is generally recognized by qualified experts as safe and effective," the letter states. The products also are considered new drugs because labeling describes them as offering sustained-release formulations, which must be approved, FDA states. The letter notes the products are reformulated versions of drugs previously marketed under the Humibid brand. The Cary, N.C. firm purchased rights to the brand name at the end of a grace period temporarily allowing continued Rx sale of single-ingredient extended-release guaifenesin products (1"The Tan Sheet" March 3, 2003, p. 4)...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS096640

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel